<DOC>
	<DOC>NCT00910741</DOC>
	<brief_summary>The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.</brief_summary>
	<brief_title>NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients with chemonaive, advanced pancreatic cancer Nonresectable, histologically or cytologically confirmed, locally advanced or metastatic pancreatic cancer Pulmonary fibrosis or interstitial pneumonia Marked pleural effusion or ascites above Grade 2 Severe drug hypersensitivity Metastasis to the central nervous system and brain</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>